Skip to main content

Table 1 Patient and treatment characteristics

From: Neutrophil-lymphocyte ratio complements volumetric staging as prognostic factor in patients treated with definitive radiotherapy for oropharyngeal cancer

Parameter  
Age median 61.6 years (range 36.9–91.4)
Gender 72% male (n = 134)
28% female (n = 53)
Histology 100% squamous cell carcinoma
Oropharyngeal subsite 52% tonsil (n = 97)
40% base of tongue (n = 75)
5% vallecula (n = 9)
2% soft palate (n = 4)
1% posterior wall (n = 2)
T stage (UICC 7th edition) 12% T1 (n = 22)
31% T2 (n = 59)
19% T3 (n = 36)
33% T4 (n = 61)
5% not available/recurrent disease (n = 9)
N stage (UICC 7th edition) 16% N0 (n = 30)
12% N1 (n = 22)
4% N2a (n = 7)
32% N2b (n = 60)
29% N2c (n = 55)
4% N3 (n = 7)
3% not available/recurrent disease (n = 6)
UICC Stage (7th edition) 8% Stage II (n = 15)
19% Stage III (n = 35)
67% Stage IVA (n = 122)
4% Stage IVB (n = 7)
2% Recurrent disease (n = 3)
ECOG performance score 80% ECOG 0 (n = 149)
15% ECOG 1 (n = 28)
5% ECOG 2 (n = 9)
Tumor volume (combined nodal and primary volume); n = events (any recurrence) median 40 cm3 (range 3–216 cm3); overall 52 events
subgroup 1–15 cm3: 14% (n = 26); 3 events
subgroup 15–70 cm3: 60% (n = 112); 28 events
subgroup 70–130 cm3: 23% (n = 43); 17 events
subgroup >130 cm3: 3% (n = 6); 4 events
Smoking status active = 62% (n = 116)
stopped =25% (n = 46)
never smoked = 13% (n = 25)
NLR median 3.33 (range 0.91–33.71)
IMRT dose prescription median 69.6 Gy (66–72 Gy)
single dose 2–2.11 Gy
Concomitant systemic therapy 42% cisplatin weekly (n = 78)
47% reduced number of cisplatin cycles (n = 87)
7% cetuximab (n = 14)
4% no systemic therapy (n = 7)
Induction chemotherapy 8% of patients (n = 15)
Follow-up median 61.2 months (range 1.7–169)